Suppr超能文献

早期霍奇金淋巴瘤的放射治疗。马萨里克纪念癌症研究所的10年经验。

Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.

作者信息

Petera J, Macharová H, Pohanková R, Malír A, Coupek P, Konecný M, Patera J, Pecina J, Drbal J, Koukalová H, Vásová I

机构信息

Masaryk Memorial Cancer Institute, Brno, Czech Republic.

出版信息

Neoplasma. 2000;47(2):129-32.

Abstract

Radiotherapy and chemotherapy, alone or in combination, are curative treatment methods in early stages of Hodgkin's disease (HD). The choice of treatment depends on the stage of the disease, histological type and localization of the tumor, as well as on other prognostic factors. A retrospective study was conducted including 145 patients with clinical Stages I and II of HD according to Ann Arbor classification, all treated in the Masaryk Memorial Cancer Institute in Brno during the years 1985 through 1994. 80 patients were males (55%) and 65 patients females (45%). The age of the patients ranged from 11 to 77 years, with an average of 34.8 years. 41 patients were diagnosed with Stage IA tumor, 1 patient with Stage IB, 75 patients with Stage IIA and 28 with Stage IIB disease. The histological types of the disease were lymphocyte predominant in 23 patients, nodular sclerosis in 49 patients, mixed cellularity in 65 cases and lymphocyte depletion in 8 cases. 91 patients were treated with radiotherapy alone. In this group 14 patients relapsed within the radiation field (15%) and 25 outside the radiation field (28%). 39 patients were treated with combination of radiotherapy and chemotherapy. In this group relapse occurred within the radiation field in 3 patients (8%) and outside the radiation field in 7 patients (18%). 15 patients were given chemotherapy alone, 7 patients from this group experienced a relapse. The five-year survival was 81% in patients with Stages IA and IIA disease, 65% in Stages IB and IIB disease. The five-year survival in the patients who relapsed was 56%. Radiotherapy remains the curative method of choice in highly selected group of patients with early stages of Hodgkin's disease. The results of radiotherapy alone are unsatisfactory in unselected clinical Stage I--II patients because of the presence of patients with adverse prognostic factors, particularly B symptomatology, mixed cellularity/lymphocyte depletion histology, higher age. These patients are candidates for combined treatment. Modern equipment and meticulous treatment are conditions crucial for the outcome of curative radiotherapy in patients with Hodgkin's disease. Combination chemotherapy is very effective in the treatment of relapse following the primary radiotherapy.

摘要

单独或联合使用放疗和化疗是霍奇金淋巴瘤(HD)早期的治愈性治疗方法。治疗方案的选择取决于疾病分期、肿瘤的组织学类型和定位,以及其他预后因素。我们进行了一项回顾性研究,纳入了145例根据Ann Arbor分类法临床分期为I期和II期的HD患者,这些患者均于1985年至1994年期间在布尔诺的马萨里克纪念癌症研究所接受治疗。其中80例为男性(55%),65例为女性(45%)。患者年龄在11岁至77岁之间,平均年龄为34.8岁。41例患者被诊断为IA期肿瘤,1例为IB期,75例为IIA期,28例为IIB期疾病。疾病的组织学类型中,淋巴细胞为主型23例,结节硬化型49例,混合细胞型65例,淋巴细胞消减型8例。91例患者仅接受放疗。该组中14例患者在放疗野内复发(15%),25例在放疗野外复发(28%)。39例患者接受放疗和化疗联合治疗。该组中3例患者在放疗野内复发(8%),7例在放疗野外复发(18%)。15例患者仅接受化疗,该组中有7例患者复发。IA期和IIA期疾病患者的五年生存率为81%,IB期和IIB期疾病患者为65%。复发患者的五年生存率为56%。对于高度选择的早期霍奇金淋巴瘤患者,放疗仍是首选的治愈方法。由于存在不良预后因素的患者,特别是有B症状、混合细胞型/淋巴细胞消减型组织学、较高年龄的患者,未经选择的临床I-II期患者单纯放疗的结果并不理想。这些患者适合联合治疗。现代设备和精心治疗是霍奇金淋巴瘤患者根治性放疗结果的关键条件。联合化疗在原发性放疗后复发的治疗中非常有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验